Clinical trials: NonSegmental Vitiligo, active
NonSegmental Vitiligo
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to < 12 years old) with nonsegmental vitiligo.
- Trial name
- NCT06804811
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 78 sites in Argentina, Austria and 12 more
- Volunteers
- 250 people
- Sponsor
- Incyte Corporation
Vitiligo
A Trial of SHR0302Base in Patients With Vitiligo
The purpose of this study is to evaluate the efficacy and safety of SHR0302Base in participants with nonsegmental vitiligo.
- Trial name
- NCT06790862
- Testing
- SHR0302Base gel
- Where
- China
- Volunteers
- 155 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Vitiligo
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
This study is to evaluate how safe and effective ritlecitinib is in participants with non-segmental vitiligo (NSV). Ritlecitinib is studied in patients with non-segmental vitiligo.
- Trial name
- Tranquillo LTE (NCT06163326)
- Testing
- Ritlecitinib, Ritlecitinib 100 mg
- Where
- 73 sites in United States, Australia and 11 more
- Volunteers
- 394 people
- Sponsor
- Pfizer
NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)
Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo
This example interventional study record describes a randomized Phase 2 clinical trial evaluating investigational Melanotan II (MT-II) as an adjunct to standard NB-UVB phototherapy for repigmentation in adults with stable…
- Trial name
- MTII-VIT (NCT07437560)
- Testing
- Melanotan II (MT-II), Narrowband UV-B (NB-UVB) phototherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hudson Biotech
Nonsegmental Vitiligo
A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
Vitiligo is a long-term autoimmune condition that causes the skin to lose its color. The body's germ-fighting system (immune system) mistakenly attacks the skin cells (melanocytes) which produce the pigment that gives the skin…
- Trial name
- NCT07108283
- Testing
- Zasocitinib
- Where
- 67 sites in United States, Canada and 7 more
- Volunteers
- 207 people
- Sponsor
- Takeda
Vitiligo - Macular Depigmentation
0.005% Latanoprost Gel for Nonsegmental Vitiligo
Latanoprost, a prostaglandin F2α (PGF2α) analog used for glaucoma treatment, is known to cause iris darkening, hypertrichosis, and periocular skin hyperpigmentation.
- Trial name
- NCT07016113
- Testing
- 0.005% latanoprost gel, 0.1% mometasone furoate cream
- Where
- Indonesia
- Volunteers
- 10 people
- Sponsor
- Universitas Padjadjaran
NonSegmental Vitiligo
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
The purpose of this study is to to evaluate the safety and efficacy of ruxolitinib cream in pediatric participants with nonsegmental vitiligo.
- Trial name
- TRuE-VIP1 (NCT06548360)
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 98 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- Incyte Corporation
NonSegmental Vitiligo
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
- Trial name
- NCT06113445
- Testing
- Povorcitinib
- Where
- 100 sites in United States, Belgium and 8 more
- Volunteers
- 467 people
- Sponsor
- Incyte Corporation
Vitiligo, Nonsegmental Vitiligo
Topical Ruxolitinib Versus Tacrolimus With Excimer Laser for Localized Vitiligo
This randomized comparative study will evaluate the efficacy and safety of topical ruxolitinib 1.5% cream compared with topical tacrolimus 0.1% ointment, each combined with 308-nm excimer laser therapy, in patients aged 12 years…
- Trial name
- NCT07909668
- Testing
- Tacrolimus 0.1% ointment, Ruxolitinib 1.5% cream, 308-nm excimer laser
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Kafrelsheikh University
Non-segmental Vitiligo
Phase 2 Study to Evaluate EI-001 in Non-segmental Vitiligo Patients
The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation.
- Trial name
- NCT07223229
- Testing
- EI-001
- Where
- 8 sites in United States, Taiwan
- Volunteers
- 45 people
- Sponsor
- Elixiron Immunotherapeutics (Hong Kong) Ltd.
Vitiligo
Comparative Efficacy of hUCMSC-Secretome Delivered Via Microneedling and Intradermal Microinjection as Adjuvant Therapy to NB-UVB in Nonsegmental Vitiligo: A Quasi-Experimental Study
The goal of this clinical trial is to analyze the effectiveness of SM-hUCMSC secretome administered via microneedling and intradermal microinjection as adjuvant therapy to NB-UVB, compared with NB-UVB alone, in terms of…
- Trial name
- Vitiligo (NCT07509242)
- Testing
- NB-UVB combined with microneedling and topical 10% secretome, receives NB-UVB combined with intradermal secretome injection, NB-UVB alone
- Where
- Indonesia
- Volunteers
- 150 people
- Sponsor
- Yohanes Firmansyah, dr, MH, MM
NonSegmental Vitiligo
A Phase 3 Study of Povorcitinib Phosphate in Chinese Adults With Nonsegmental Vitiligo
This Phase 3 study will evaluate the efficacy and safety of oral povorcitinib phosphate compared with placebo in Chinese adults with nonsegmental vitiligo who are considered suitable for systemic therapy.
- Trial name
- NCT07865312
- Testing
- Povorcitinib phosphate
- Where
- 44 sites in China
- Volunteers
- 174 people
- Sponsor
- Dermavon Holdings Limited
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental vitiligo.
- Trial name
- Tranquillo 2 (NCT06072183)
- Testing
- Ritlecitinib
- Where
- 229 sites in United States, Australia and 16 more
- Volunteers
- 1,571 people
- Sponsor
- Pfizer
NonSegmental Vitiligo
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.
- Trial name
- NCT06113471
- Testing
- Povorcitinib
- Where
- 86 sites in United States, Bulgaria and 7 more
- Volunteers
- 450 people
- Sponsor
- Incyte Corporation